Syngen Biotech (8279.TWO) Earnings Analysis

Syngen Biotech (8279.TWO) has no confirmed upcoming earnings date. It has beaten estimates in 0/5 recent quarters (0%). Trailing P/E 9.81.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 8279.TWO next report earnings?

No confirmed upcoming earnings date is currently scheduled for 8279.TWO. This page updates as the calendar is published.

8279.TWO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-271.23 TWDn/an/an/a
2026-03-031.4 TWD2.77 TWD-49.5%Miss
2025-04-282.25 TWD2.77 TWD-18.8%Miss
2025-03-042.15 TWD2.18 TWD-1.4%Miss
2024-10-312.67 TWD3.24 TWD-17.6%Miss
2024-08-011.84 TWD3.18 TWD-42.1%Miss

Beat rate: 0/5 (0%) over reported quarters with consensus data.

8279.TWO valuation and analyst view

Trailing P/E9.81
Trailing EPS8.985 TWD
Price / book1.05
Dividend yield5.66%
Market cap2.40B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Syngen Biotech (8279.TWO)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 8279.TWO. This page updates as the calendar is published.

Did 8279.TWO beat earnings last quarter?

Consensus estimate data was not available for 8279.TWO's 2026-04-27 report.

What is 8279.TWO's earnings track record?

Over the last 5 reported quarters with consensus data, 8279.TWO beat estimates 0 times (0%).

What is 8279.TWO's current P/E ratio and EPS?

8279.TWO trades at a trailing P/E of 9.81 on trailing EPS of 8.985186240188673 TWD.

What do analysts rate 8279.TWO?

8279.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.